Search
Search Results
-
Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study
Background and ObjectiveA new gastric cancer screening scoring system (NGCS) strategy was recommended for the early gastric cancer (GC) screening...
-
Cost-effectiveness analysis of ranibizumab for retinal vein occlusion patients in China from the societal perspective
BackgroundClinical trials in China have demonstrated that ranibizumab can improve the clinical outcomes of branch retinal vein occlusion (BRVO) and...
-
Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial
IntroductionThe efficacy and safety of empagliflozin in the treatment of heart failure with preserved ejection fraction (HFpEF) were demonstrated in...
-
Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China
BackgroundCamrelizumab combined with rivoceranib has been proven effective for treating unresectable hepatocellular carcinoma (uHCC). However, their...
-
The role of budget impact and its relationship with cost-effectiveness in reimbursement decisions on health technologies in the Netherlands
Health authorities using cost-effectiveness analysis (CEA) for informing reimbursement decisions on health technologies increasingly require economic...
-
Cost-Effectiveness Analysis of Abrocitinib Compared with Other Systemic Treatments for Severe Atopic Dermatitis in Spain
IntroductionAtopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by itchy, painful, and dry skin. Despite the great number of...
-
Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
ObjectivesThis study was aimed to systematically review published economic studies to determine whether dapagliflozin, a sodium-glucose...
-
Validation and comparison of five preference-based measures among age-related macular degeneration patients: evidence from mainland China
PurposeTo compare the psychometric properties of five preference-based measures (PBMs) among patients with age-related macular degeneration (AMD) in...
-
Analysis of oncological drugs authorised in Spain in the last decade: association between clinical benefit and reimbursement
BackgroundOur study aimed to assess whether there was a relationship between clinical benefits and reimbursement decisions as well as the inclusion...
-
Economic evaluation of adjuvant therapy with osimertinib in patients with early-stage non–small cell lung cancer and mutated EGFR
PurposeThe ADAURA trial demonstrated the superiority of osimertinib over a placebo with regard to disease-free survival, showing it to be indicated...
-
Cost-effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in Malaysia
SummaryFrom the perspective of Malaysian health care providers, denosumab was cost-effective in the treatment of postmenopausal osteoporosis, with an...
-
Cost-Effectiveness of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease from Chinese Healthcare Perspective
IntroductionTo assess the cost-effectiveness of evolocumab with statins versus placebo combined with statins in the treatment of adult patients with...
-
National Healthcare Economic Evaluation Guidelines: A Cross-Country Comparison
Background and ObjectivesGlobally, a number of countries have developed guidelines that describe the design and conduct of economic evaluations as...
-
Cost-Utility Analysis of CYP2C19 Genotype Detection for Selection of Acid-Suppressive Therapy with Lansoprazole or Vonoprazan for Patients with Reflux Esophagitis in China
BackgroundThe cytochrome P450 (CYP) 2C19 genotype has a profound effect on the efficacy of lansoprazole, with less of an influence on vonoprazan....
-
Evaluating vonoprazan and tegoprazan for gastroesophageal reflux disease treatment in Chinese Healthcare: an EVIDEM framework analysis
BackgroundIn Chinese healthcare settings, drug selection decisions are predominantly influenced by the Pharmacy & Therapeutics Committee (PTC). This...
-
Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China
ObjectiveIn frst-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC), the ORIENT-11 study demonstrated a...
-
Cost-effectiveness of edaravone dexborneol versus dl-3-n-butylphthalide for the treatment of acute ischemic stroke: a Chinese health care perspective
BackgroundEdaravone dexborneol and dl-3-n-butylphthalide are two innovative brain cytoprotective drugs from China that have been approved and widely...
-
Comparative policy analysis of national rare disease funding policies in Australia, Singapore, South Korea, the United Kingdom and the United States: a sco** review
BackgroundRare diseases pose immense challenges for healthcare systems due to their low prevalence, associated disabilities, and attendant treatment...
-
Cost-effectiveness Analysis of Maternal Immunization with RSVpreF Vaccine for the Prevention of Respiratory Syncytial Virus Among Infants in Spain
IntroductionRespiratory syncytial virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in children under one year of age. In...
-
Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers
Background and ObjectiveThis study aimed to assess the cost-effectiveness of two regimens regarded as the standard of care for the treatment of newly...
